Publicaciones en colaboración con investigadores/as de Yale School of Medicine (42)

2024

  1. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

    Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272

  2. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 403, Núm. 10423, pp. 249-260

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Clinical outcomes and quality of life after contemporary isolated coronary bypass grafting: a prospective cohort study

    International journal of surgery (London, England), Vol. 109, Núm. 4, pp. 707-715

  3. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

    Blood

  4. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  5. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study

    Annals of Hematology, Vol. 102, Núm. 2, pp. 311-321

2022

  1. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  2. Clinical event rate in patients with and without left main disease undergoing isolated coronary artery bypass grafting: results from the European DuraGraft Registry

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 62, Núm. 4

  3. Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs

    Human Brain Mapping, Vol. 43, Núm. 1, pp. 300-328

  4. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

    Leukemia, Vol. 36, Núm. 5, pp. 1432-1435

  5. Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems

    Seminars in Liver Disease, Vol. 42, Núm. 1, pp. 087-103

  6. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

    Blood

  7. Surgical resection of Masaoka stage III thymic epithelial tumours with great vessels involvement: a retrospective multicentric analysis from the European Society of Thoracic Surgeons thymic database

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 62, Núm. 4

  8. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. Erratum: Thymomectomy plus total thymectomy versus simple thymomectomy for early-stage thymoma without myasthenia gravis: A European Society of Thoracic Surgeons Thymic Working Group Study (European Journal of Cardio-Thoracic Surgery (2021) 60 (881-887) DOI: 10.1093/ejcts/ezab224)

    European Journal of Cardio-thoracic Surgery

  2. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics

    Cytometry Part B - Clinical Cytometry, Vol. 100, Núm. 2, pp. 142-155

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: Assay development/optimization, validation, and ongoing quality monitors

    Cytometry Part B - Clinical Cytometry, Vol. 100, Núm. 2, pp. 156-182

  5. Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey

    Frontiers in Psychiatry, Vol. 12